Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
1.680
+0.020 (1.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Nexalin Technology Revenue
In the year 2024, Nexalin Technology had annual revenue of $168.72K with 52.35% growth. Nexalin Technology had revenue of $27.18K in the quarter ending December 31, 2024, with 32.35% growth.
Revenue (ttm)
$168.72K
Revenue Growth
+52.35%
P/S Ratio
92.23
Revenue / Employee
$28,120
Employees
6
Market Cap
22.35M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NXL News
- 3 days ago - Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - GlobeNewsWire
- 15 days ago - Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - GlobeNewsWire
- 22 days ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval - GlobeNewsWire
- 7 weeks ago - Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board - GlobeNewsWire
- 2 months ago - Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment - GlobeNewsWire
- 2 months ago - Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewsWire